 The results of this study indicate that both circulating depeptidilpeptidase 3, DPP3, and adrenomedulin, bioADM, levels are associated with short-term mortality and acute kidney injury, aka in critically ill COVID-19 patients. Furthermore, patients with high levels of both DPP3 and bioADM have an additional increased risk of death within 28 days after hospitalization. This suggests that treatment with specific antibodies targeting DPP3 or bioADM-related pathways could potentially improve outcomes of COVID-19. This article was authored by Dirk van Liya, Benjamin De Nio, Kareen Santos, and others.